Solara Active Pharma Sciences (NSE:SOLARA) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SOLARA Solara Active Pharma Sciences Ltd NSE:SOLARA
68 GF Score
Price ₹570.80
GF Value ₹571.88
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Solara Active Pharma Sciences Notes Receivable?

Solara Active Pharma Sciences NSE:SOLARA -1.25% 68 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SOLARA with a GF Score™ of 68/100 and a GF Value™ of ₹571.88 (Fairly Valued). The stock has 3 warning signs investors should review.

Solara Active Pharma Sciences's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Solara Active Pharma Sciences Notes Receivable Related Terms

Solara Active Pharma Sciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for Solara Active Pharma Sciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solara Active Pharma Sciences Notes Receivable Chart

Solara Active Pharma Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Solara Active Pharma Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SOLARA
68GF Score
Solara Active Pharma Sciences Ltd NSE:SOLARA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solara Active Pharma Sciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Solara Active Pharma Sciences (NSE:SOLARA) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Solara Active Pharma Sciences and its competitors.
Is Solara Active Pharma Sciences' Notes Receivable too high?
Solara Active Pharma Sciences' current Notes Receivable is ₹0 Mil. Overall, Solara Active Pharma Sciences has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Notes Receivable compare to ZTS and UTHR?
Solara Active Pharma Sciences' Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Solara Active Pharma Sciences and its competitors. Solara Active Pharma Sciences's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Based on GuruFocus' analysis, Solara Active Pharma Sciences (NSE:SOLARA) is currently considered Fairly Valued. The stock's GF Value™ is ₹571.88, compared to a current price of ₹570.80 — trading 0.2% below its estimated fair value. The current Notes Receivable is ₹0 Mil. Solara Active Pharma Sciences' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARA), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solara Active Pharma Sciences (NSE:SOLARA) Overvalued in 2026?

Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be undervalued. The current stock price of ₹570.80 is trading 0.2% below its estimated GF Value™ of ₹571.88. GuruFocus considers Solara Active Pharma Sciences to be Fairly Valued.

Key valuation signals for NSE:SOLARA:

  • Notes Receivable: ₹0 Mil
  • GF Value™: ₹571.88 vs. price of ₹570.80 (0.2% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the NSE:SOLARA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Solara Active Pharma Sciences Business Description

Other Exchanges 541540:India
Address Phase II - CSIR Road, Module No. 601, 602, 603, Ticel Bio Park, Taramani, Chennai, TN, IND, 600113
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
68GF Score

Get the complete analysis for NSE:SOLARA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹570.80
Price
₹571.88
GF Value